Breast Cancer Clinical Trial
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
Summary
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
Eligibility Criteria
Inclusion Criteria:
Women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2-
Scheduled to undergo upfront surgery
Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines
Exclusion Criteria:
History of breast cancer
Receipt of ET for risk reduction in the previous 3 months
Stage IV disease at presentation
Scheduled to undergo neoadjuvant systemic chemotherapy
Pregnant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States More Info
How clear is this clinincal trial information?